Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.
Journal
JACS Au
ISSN: 2691-3704
Titre abrégé: JACS Au
Pays: United States
ID NLM: 101775714
Informations de publication
Date de publication:
27 Dec 2021
27 Dec 2021
Historique:
received:
05
11
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
4
1
2022
Statut:
epublish
Résumé
Integrins α4β1/ α9β1 are important in the pathogenesis and progression of inflammatory and autoimmune diseases by their roles in leukocyte activation and trafficking. Natalizumab, a monoclonal antibody selectively targeting α4β1 integrin and blocking leukocyte trafficking to the central nervous system, is an immunotherapy for multiple sclerosis (MS). However, due to its adverse effects associated with chronic treatment, alternative strategies using small peptide mimetic inhibitors are being sought. In the present study, we synthesized and characterized visabron
Identifiants
pubmed: 34977904
doi: 10.1021/jacsau.1c00496
pmc: PMC8717366
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2361-2376Informations de copyright
© 2021 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Adv Biol Regul. 2012 May;52(2):326-39
pubmed: 22781746
Biochim Biophys Acta. 2009 Jun;1790(6):431-44
pubmed: 19289150
Biochemistry. 2014 Sep 16;53(36):5771-8
pubmed: 25153342
Nat Rev Neurol. 2010 Dec;6(12):667-79
pubmed: 21131916
Biochem J. 2006 Apr 15;395(2):385-92
pubmed: 16411889
Biomed Pharmacother. 2018 Dec;108:1565-1571
pubmed: 30372858
J Chem Inf Model. 2007 Jul-Aug;47(4):1395-404
pubmed: 17569522
ACS Chem Biol. 2016 May 20;11(5):1220-9
pubmed: 26841170
Toxins (Basel). 2018 Nov 20;10(11):
pubmed: 30463321
Cell Signal. 2015 Jun;27(6):1225-36
pubmed: 25748048
Biochem J. 2019 Feb 28;476(4):705-718
pubmed: 30819933
Biochem J. 2003 Jun 15;372(Pt 3):725-34
pubmed: 12667142
Biochem J. 2001 Jan 15;353(Pt 2):181-91
pubmed: 11139379
J Med Chem. 2003 Dec 18;46(26):5752-62
pubmed: 14667228
J Pharmacokinet Biopharm. 1992 Aug;20(4):319-31
pubmed: 1479558
Nat Rev Drug Discov. 2012 Dec;11(12):909-22
pubmed: 23197038
Ther Adv Neurol Disord. 2017 Sep;10(9):327-336
pubmed: 28861122
J Biol Chem. 2013 Nov 8;288(45):32314-32325
pubmed: 24047894
J Proteome Res. 2007 Jan;6(1):326-36
pubmed: 17203976
Expert Opin Ther Pat. 2018 Dec;28(12):903-917
pubmed: 30444683
Toxicon. 2011 Sep 15;58(4):355-62
pubmed: 21801741
Biopolymers. 2000 Jun;53(7):565-80
pubmed: 10766952
Trends Pharmacol Sci. 2012 Jul;33(7):405-12
pubmed: 22633092
Am J Physiol Cell Physiol. 2012 Jan 1;302(1):C154-64
pubmed: 21956165
J Med Chem. 2001 Aug 2;44(16):2586-92
pubmed: 11472212
J Med Chem. 2008 Feb 28;51(4):1026-34
pubmed: 18220330
Nat Rev Drug Discov. 2021 Jan;20(1):39-63
pubmed: 33077936
J Pharmacokinet Biopharm. 1993 Aug;21(4):457-78
pubmed: 8133465
J Med Chem. 2002 Apr 11;45(8):1665-71
pubmed: 11931620
Int Immunol. 2015 Jan;27(1):47-53
pubmed: 25326459
J Med Chem. 1999 Mar 11;42(5):920-34
pubmed: 10072689
Methods Mol Biol. 2020;2068:3-26
pubmed: 31576520
J Pharmacol Toxicol Methods. 2018 Sep - Oct;99:106609
pubmed: 31284073
Biochemistry. 2004 Feb 17;43(6):1639-47
pubmed: 14769041
J Med Chem. 2011 Jul 28;54(14):5154-64
pubmed: 21650457
Toxicon. 2013 Mar 15;64:96-105
pubmed: 23319078
J Biol Chem. 2000 Oct 13;275(41):31930-7
pubmed: 10926928
Pharmacol Toxicol. 2002 Dec;91(6):313-20
pubmed: 12688374
Comp Biochem Physiol B Biochem Mol Biol. 2009 Jul;153(3):253-60
pubmed: 19296915
Haematologica. 2009 Nov;94(11):1493-501
pubmed: 19608669
Methods Mol Biol. 2020;2068:205-223
pubmed: 31576530
J Biol Chem. 1995 Sep 29;270(39):23196-202
pubmed: 7559467
Cell. 1992 Apr 3;69(1):11-25
pubmed: 1555235
Cancer Biol Ther. 2009 Aug;8(15):1507-16
pubmed: 19502781
J Cell Commun Signal. 2018 Mar;12(1):333-342
pubmed: 28975544
Br J Pharmacol. 1999 Apr;126(8):1751-60
pubmed: 10372817
Adv Drug Deliv Rev. 2016 Jun 1;101:34-41
pubmed: 27154268
Pharm Res. 2013 Dec;30(12):3029-44
pubmed: 23686373
Front Chem. 2020 Nov 12;8:532577
pubmed: 33282822
Gene. 2004 Aug 4;337:55-69
pubmed: 15276202
FEBS Lett. 2004 Nov 19;577(3):478-82
pubmed: 15556632
Front Immunol. 2020 Sep 24;11:549842
pubmed: 33072089